CLC number:
On-line Access: 2021-02-03
Received: 2020-08-19
Revision Accepted: 2020-11-16
Crosschecked: 0000-00-00
Cited: 0
Clicked: 3993
Department of Medical Genetics, Faculty of Medicine, Umm Al-Qura University, P.O. Box 715, Mecca 21955, Kingdom of Saudi Arabia; Science and Technology Unit, Umm Al-Qura University, P.O. Box 715, Mecca 21955, Kingdom of Saudi Arabia; The Regional Laboratory, Molecular Diagnostics Unit, Department of Molecular Biology, Ministry of Health (MOH), P.O. Box 6251, Mecca, Kingdom of Saudi Arabia; Department of Pathology and Lab Medicine, University of Ottawa, 451 Smyth Road, Ottawa, ON K1H 8M5, Canada. Peptides-based vaccine against SARS-nCoV-2 antigenic fragmented synthetic epitopes recognized by T cell and β-cell initiation of specific antibodies to fight the infection[J]. Journal of Zhejiang University Science D, 2021, 4(3): 490-505.
@article{title="Peptides-based vaccine against SARS-nCoV-2 antigenic fragmented synthetic epitopes recognized by T cell and β-cell initiation of specific antibodies to fight the infection",
author="Department of Medical Genetics, Faculty of Medicine, Umm
Al-Qura University, P.O. Box 715, Mecca 21955, Kingdom of
Saudi Arabia; Science and Technology Unit, Umm Al-Qura University, P.O.
Box 715, Mecca 21955, Kingdom of Saudi Arabia; The Regional Laboratory, Molecular Diagnostics Unit,
Department of Molecular Biology, Ministry of Health
(MOH), P.O. Box 6251, Mecca, Kingdom of Saudi Arabia; Department of Pathology and Lab Medicine, University of
Ottawa, 451 Smyth Road, Ottawa, ON K1H 8M5, Canada",
journal="Journal of Zhejiang University Science D",
volume="4",
number="3",
pages="490-505",
year="2021",
publisher="Zhejiang University Press & Springer",
doi="10.1007/s42242-020-00114-3"
}
%0 Journal Article
%T Peptides-based vaccine against SARS-nCoV-2 antigenic fragmented synthetic epitopes recognized by T cell and β-cell initiation of specific antibodies to fight the infection
%A Department of Medical Genetics
%A Faculty of Medicine
%A Umm
Al-Qura University
%A P.O. Box 715
%A Mecca 21955
%A Kingdom of
Saudi Arabia
%A Science and Technology Unit
%A Umm Al-Qura University
%A P.O.
Box 715
%A Mecca 21955
%A Kingdom of Saudi Arabia
%A The Regional Laboratory
%A Molecular Diagnostics Unit
%A
Department of Molecular Biology
%A Ministry of Health
(MOH)
%A P.O. Box 6251
%A Mecca
%A Kingdom of Saudi Arabia
%A Department of Pathology and Lab Medicine
%A University of
Ottawa
%A 451 Smyth Road
%A Ottawa
%A ON K1H 8M5
%A Canada
%J Journal of Zhejiang University SCIENCE D
%V 4
%N 3
%P 490-505
%@ 1869-1951
%D 2021
%I Zhejiang University Press & Springer
%DOI 10.1007/s42242-020-00114-3
TY - JOUR
T1 - Peptides-based vaccine against SARS-nCoV-2 antigenic fragmented synthetic epitopes recognized by T cell and β-cell initiation of specific antibodies to fight the infection
A1 - Department of Medical Genetics
A1 - Faculty of Medicine
A1 - Umm
Al-Qura University
A1 - P.O. Box 715
A1 - Mecca 21955
A1 - Kingdom of
Saudi Arabia
A1 - Science and Technology Unit
A1 - Umm Al-Qura University
A1 - P.O.
Box 715
A1 - Mecca 21955
A1 - Kingdom of Saudi Arabia
A1 - The Regional Laboratory
A1 - Molecular Diagnostics Unit
A1 -
Department of Molecular Biology
A1 - Ministry of Health
(MOH)
A1 - P.O. Box 6251
A1 - Mecca
A1 - Kingdom of Saudi Arabia
A1 - Department of Pathology and Lab Medicine
A1 - University of
Ottawa
A1 - 451 Smyth Road
A1 - Ottawa
A1 - ON K1H 8M5
A1 - Canada
J0 - Journal of Zhejiang University Science D
VL - 4
IS - 3
SP - 490
EP - 505
%@ 1869-1951
Y1 - 2021
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1007/s42242-020-00114-3
Abstract: The World Health Organization has declared the rapidly spreading coronavirus to be a global pandemic. The FDA is yet to approve a vaccine for human novel coronavirus. Here, we developed a peptide-based vaccine and used high-throughput screening by molecular dynamics simulation to identify T-cell- and β-cell-recognized epitopes for producing specific antibodies against SARS-nCoV-2. We construct ~ 12 P′ antigenic epitope peptides to develop a more effective vaccine and identify specific antibodies. These epitope peptides selectively presented the best antigen presentation scores for both human pMHC class I and II alleles to develop a strong binding affinity. All antigens identified of SARS-nCoV-2 different proteins by each attached specific ~ 1–7 L linker adaptor were used to construct a broad single peripheral peptide vaccine. It is expected to be highly antigenic with a minimum allergic effect. As a result of these exciting outcomes, expressing a vaccine using the intimated peptide was highly promising and positive to be highly proposed as epitope-based peptide vaccine of specific antibody against SARS-nCoV-2 by initiating T cells and β-cells. An in vitro study for the proposed peptide-based vaccine is mostly recommended. Further clinical trials are required to check the efficacy of this vaccine.
Open peer comments: Debate/Discuss/Question/Opinion
<1>